The document discusses implementing digital pathology at The Christie Hospital in Manchester. It describes a digital pathology pilot study conducted across Greater Manchester as part of the Cancer Vanguard Initiative. The study found that digital pathology could help reduce diagnosis time by allowing fast sharing of samples among specialists. However, the pilot also encountered some technical challenges, such as the IT system becoming overloaded. The document argues that digital pathology, combined with workflow and infrastructure improvements, has the potential to make pathology services more efficient and enhance patient care.
1 of 125
Downloaded 31 times
More Related Content
Digital Pathology - Implementing it in a Leading Cancer Centre
1. The Christie NHS Foundation Trust
Digital Pathology
Implementing it in a
leading Cancer Centre ¡
Dr. Pedro Oliveira
Dept. of Pathology / The Christie Hospital
Poland, and with great relief to the team (not that it
was ever in doubt) the conference was awarded to
Manchester by the global steering committee.
PTCOG 55 will be held in Manchester in June 2019,
showcasing the Christie service on the national stage and
bringing an estimated ?1.4m into the local economy.
Thanks to everyone who made this proposal such a
success.
Readers interested to read the bid book itself can get in
touch with Jim Weightman (link opposite).
Proton Beam Therapy
The Christie NHS Foundation Trust
Wilmslow Road,
Manchester, M20 4BX
Phone: 0161 918 2190
E-mail: James.Weightman@christie.nhs.uk
12. The Christie NHS Foundation Trust
I am quiet confident that a
2017 Histopathologist can
do a diagnosis of Basal Cell
Carcinoma with the 1667
microscope ¡
13. The Christie NHS Foundation Trust
Microscope as a Tool ¡
Simple
Reliable technology
Resistant
14. The Christie NHS Foundation Trust
Why no
conventional
radiology
film?
15. The Christie NHS Foundation Trust
Why no
Photographic
film cameras?
23. The Christie NHS Foundation Trust
We have been using
¡°graticules¡± ¡
We can use ¡°static images¡± for
assessing ER, PR, Ki-67, ¡
We can use ¡°stereological
methods¡± on images taken ¡
24. The Christie NHS Foundation Trust
Image Analysis by
Digital Pathology is
¡°easier¡± and ¡°faster¡±
but not forcefully
¡°better¡±!
25. The Christie NHS Foundation Trust
Do you believe that your Trust
bought a CT scan because of
¡°Hounsfield unit¡± capabilities?
26. The Christie NHS Foundation Trust
How much of your
current time as a
Histopathologist
do you dedicate to
¡°image analysis¡±?
27. The Christie NHS Foundation Trust
Myth #2
Image Analysis
= Digital
Pathology!
28. The Christie NHS Foundation Trust
Myth #3
Cost effective
= Digital
Pathology!
49. The Christie NHS Foundation Trust
2016
CEff 220616 1 V1 Final
Pathology reporting of breast disease in surgical excision specimens
incorporating the dataset for histological reporting of breast cancer
June 2016
Authors: Professor IO Ellis (Chair) Dr S Al-Sam Dr N Anderson
Dr P Carder Dr R Deb Dr A Girling
Dr S Hales Professor A Hanby Dr M Ibrahim
Dr AHS Lee Dr R Liebmann Dr E Mallon
Professor SE Pinder Dr E Provenzano Dr C Quinn
Dr E Rakha Dr D Rowlands
Professor T Stephenson Dr C A Wells
Unique document number G148 HR (This publication contains high-resolution images and is 12 MB. It
is also available on www.rcpath.org as a 4 MB PDF, with lower-res images.)
Document name Pathology reporting of breast disease in surgical excision specimens
incorporating the dataset for histological reporting of breast cancer
Version number 2
Produced by The authors are members of the Guidelines Working Group of the UK
National Coordinating Committee for Breast Pathology, which leads on
developing pathology guidance for the NHS Breast Screening Programme
(NHSBSP) and for preparation of dataset standards in breast cancer
pathology for The Royal College of Pathologists. Dr Ibrahim is a member of
UK NEQAS and was co-opted to the Working Group to assist with the
sections regarding quality assurance of immunocytochemical predictive
testing for hormone receptors and HER2. Dr Liebmann provided guidance
on RCPath policy including standards for hormone receptor evaluation. Dr
Rakha is a member of the Research Sub-Committee of the UK National
Coordinating Committee for Breast Pathology.
Date active June 2016
Date for review May 2019
Comments This document updates the NHSBSP Guidelines for Pathology Reporting in
Breast Cancer Screening and The Royal College of Pathologists¡¯ Standards
and datasets for reporting cancers: Dataset for histological reporting of
breast cancer. It replaces the previous Minimum dataset for breast cancer
histopathology, published in 2005.
In accordance with the College¡¯s pre-publications policy, it was on the
College website for consultation from 21 October to 18 November 2015.
Thirty-six items of feedback were received and the document was amended
accordingly. Please email publishing@rcpath.org to see the responses and
comments.
In June 2016, Appendix M was amended to correct the coding for hamartoma.
Dr Lorna Williamson
Director of Publishing and Engagement
CEff 220616 123 V1 Final
Appendix B RCPath dataset for histopathological reporting of breast cancer
surgical resections (in situ and invasive disease)
This section lists the items recognised as core cancer dataset fields. These have been
incorporated into a recommended synoptic reporting format in Appendix A.
Surname: ¡¡¡¡¡¡¡¡¡¡¡¡ Forenames: ¡¡¡¡¡¡¡ Date of birth: ¡¡¡¡¡¡
Sex: ¡.¡¡. Hospital:¡¡¡¡¡¡.. ¡¡¡¡¡.¡.. Hospital/CHI no: ¡¡¡¡¡¡¡.¡¡¡..
NHS no: ¡¡¡¡¡¡¡¡¡¡ Date of surgery: ¡¡¡¡¡¡.¡¡¡¡ Date of report ¡¡¡..
Authorisation: ¡¡¡¡¡.. Report no: ¡¡¡¡¡¡¡¡¡.Date of receipt:¡¡¡¡¡¡¡¡...
Pathologist: ¡¡¡¡¡.¡¡¡¡¡¡¡¡¡... Surgeon: ¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡.. ¡
Surgical specimen(s)
Is there a history of neo-adjuvant therapy?* Yes ¡õ No ¡õ Not known ¡õ
Side:* Right ¡õ Left ¡õ
Specimen type:*
WLE ¡õ Excision biopsy ¡õ Localisation specimen ¡õ Segmental excision ¡õ
Mastectomy ¡õ Subcutaneous mastectomy ¡õ
Re-excision ¡õ Further margins (including cavity shaves/bed biopsies)
Microdochectomy/microductectomy ¡õ
SLN ¡õ Axillary sampling ¡õ Axillary LN level I ¡õ
Axillary LN level II ¡õ Axillary LN level III ¡õ Total duct excision/Hadfield¡¯s procedure ¡õ
Other ..........................................................
Specimen weight (g) ..........................................
Malignant lesions
Malignant in situ lesion:
In situ components:
DCIS grade:* High ¡õ Intermediate ¡õ Low ¡õ Cannot be assessed ¡õ
DCIS/pleomorphic or DCIS like LCIS size mm: ...........................................
LCIS: Present ¡õ Not identified ¡õ
Paget¡¯s disease: Present ¡õ Not identified ¡õ Cannot be assessed ¡õ
Microinvasive: Present ¡õ Not identified ¡õ
Invasive carcinoma
Size and extent
Invasive tumour size (mm): * ...................................
Whole tumour (invasive + DCIS) size (mm): * ...............................
Disease extent:* Localised ¡õ Multiple invasive foci ¡õ Cannot be assessed ¡õ
¡ a document
of more than
100 pages!
¡ a template
of #4 pages!
63. The Christie NHS Foundation Trust
It is time for Digital Pathology
64. The Christie NHS Foundation Trust
30/11/17, 00:13Digital pathology project is under way | Greater Manchester Cancer Vanguard Innovation
Digital pathology project is
under way
Oct 2, 2017 | news
A project to test out the latest technology in cancer pathology is
under way across Greater Manchester.
Vanguard Innovation is exploring the use of digital pathology that
can capture a digital image of human tissue samples. Also known
as on-screen microscopy, the technique allows samples to be
shared quickly among specialists and so has the potential to
reduce the time it takes to reach a ?nal diagnosis when second
opinions are required.
Latest
news
Pioneering
website helps
patient
decision-
making
¡®You get so
much from
giving¡¯
Wellbeing
website up
and running
Pilot scheme
aims to boost
early cancer
diagnosis
Online
education
platform
passes
milestone
Search
about usabout us newsnews user involvementuser involvement showcasesshowcases gateway-cgateway-c videosvideos
newslettersnewsletters contactcontact
Digital pathology project is
under way
Oct 2, 2017 | news
A project to test out the latest technology in cancer pathology is
under way across Greater Manchester.
Vanguard Innovation is exploring the use of digital pathology that
can capture a digital image of human tissue samples. Also known
Latest
news
Pioneering
website helps
patient
decision-
making
¡®You get so
much from
giving¡¯
Wellbeing
website up
and running
Pilot scheme
aims to boost
early cancer
diagnosis
Online
Search
newslettersnewsletters contactcontact
65. The Christie NHS Foundation Trust
Do we need to validate
Digital Pathology?
66. The Christie NHS Foundation Trust
When you bought your
Plasma HD TV did you
¡°validate¡± it ?
67. The Christie NHS Foundation Trust
What have we learnt at
Christie from the ¡
Digital Pathology Cancer
Vanguard Pilot Study in
Greater Manchester?
89. The Christie NHS Foundation Trust
Build a new Gateshead-like
pathology ¡°factory¡± in Manchester ¡
90. The Christie NHS Foundation Trust
Fill with ¡°State of the Art¡± LEAN pathology
continuous work?ow ¡
91. The Christie NHS Foundation Trust
New ef?cacious LIMS and IT solutions ¡
92. The Christie NHS Foundation Trust
Bring the specimens to the new central
factory (less than 20 miles distance) ¡
TissueSAFE
High vacuum biospecimens transfer system
FORMALIN-FREE
Double layered
microns in thick
greater mechan
resistance to pe
Available in five
dimensions, sui
specimens.
Three sealing a
lines marked fo
Sealable docum
security for pati
Automatically p
label contains: I
specimen and fi
Enlarged base f
SPECIAL BAGS
Full automation and closed operation prevents exposure to formalin fu
Storage in vacuum bags dramatically reduces volume.
Archiving even without formalin is possible.
Improved archiving
Lower disposal cost thanks to a decreased volume of bio-hazard mater
Extreme cost saving for disposal
A
D
C
B
E
A
D
C
B
E
93. The Christie NHS Foundation Trust
Delegate ¡°cut-up¡± in properly trained
Biomedical Scientists ¡
94. The Christie NHS Foundation Trust
¡°Rapid processor¡±¡
¡°Automatic embedding¡±¡
95. The Christie NHS Foundation Trust
Hirata received "The Japan Machinery Federation Chairman
Award" in the 6th Robot
Hirata Corporation is pleased to announce we and Sakura Finetek Japan Co.,Ltd.£¨http://www.sakura-
?netek.com/), a medical equipment manufacturer, receive "The Japan Machinery Federation Chairman Award"
in our joint names. Hirata designs and produces fully automatic continuous slicer Tissue-Tek Smart Section
for preparing pathological sample on consignment contract with Sakura Finetek Japan Co.,Ltd.. This slicer is
highly-regarded as a social value product.
In medical equipment industry, more and more system automation is required because of heavy burden on